Top Pharma Companies Intensify Clinical Trial Terminations in 2025 Amid Strategic R&D Restructuring

　　【Pharmaceutical Network Industry DynamicsBy 2025, the failure of innovative drug development has become very common worldwide. Recently, leading pharmaceutical companies such as Johnson & Johnson, Novo Nordisk, Eli Lilly, and Takeda have been intensively terminating clinical trials for new drugs.
 

On December 11, Rezolute announced that its hypoglycemia treatment drug did not meet the primary endpoint in the sunRIZE Phase III trial (the target of reducing hypoglycemic events by 45% was not achieved). The sunRIZE study is a multicenter, randomized, double-blind, placebo-controlled registration study designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism who have poor hypoglycemia control, covering participants aged 3 months to 45 years.
 

On November 24, Novo Nordisk announced that two Phase III clinical trials (EVOKE and EVOKE+) of oral semaglutide for the treatment of early Alzheimer's disease did not meet the primary endpoint. The trials failed to demonstrate that semaglutide was superior to placebo in slowing the progression of Alzheimer's disease, with the assessment mainly based on changes from baseline in the Clinical Dementia Rating-Sum of Boxes score. Based on the observed efficacy results, the one-year extension periods in the EVOKE and EVOKE+ trials will be terminated.
 

On November 21, Johnson & Johnson terminated the Phase II clinical trial of the anti-Tau protein antibody posdinemab, as the drug failed to meet the primary efficacy endpoint in the Phase 2b clinical trial AUτonomy. Posdinemab is a humanized IgG1 monoclonal antibody, and early Phase 1 clinical trial results had shown potential in reducing pT217 levels in cerebrospinal fluid. This clinical setback reveals that anti-tau immunotherapy still faces significant scientific challenges.
 

On November 18, Bristol-Myers Squibb and Johnson & Johnson jointly announced the termination of the Phase III clinical trial of the Factor XIa inhibitor milvexian for ACS. The trial aimed to evaluate the efficacy and safety of milvexian when used in combination with standard treatment (conventional antiplatelet therapy) in patients with recent onset of Acute Coronary Syndrome (ACS). This decision to terminate was based on the pre-specified interim analysis results from the Independent Data Monitoring Committee (IDMC), indicating that the trial was unlikely to meet its primary efficacy endpoint.
 

On October 30, Bristol-Myers Squibb, Eli Lilly, and Takeda simultaneously announced the termination of six clinical-stage projects, covering popular therapeutic areas such as oncology, chronic pain, and neurological diseases...
 

Overall, the large-scale termination of clinical trials by pharmaceutical companies in 2025 is not simply a "failure," but an inevitable transformation of the innovative drug industry from "uncontrolled growth" to "meticulous cultivation." Clinical value prioritization has become a rigid standard, and pharmaceutical companies are becoming stricter in evaluating R&D projects. They are no longer blindly investing in targets with repeated past failures or difficult-to-treat diseases. In the future, the industry is expected to build a more efficient and sustainable R&D model through three major pathways: precise focus, technological empowerment, and risk management.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.